This issue of Otolaryngologic Clinics, guest edited by Drs. Sarah K. Wise, Ashkan Monfared, and Nicole C. Schmitt is devoted to Biologics in Otolaryngology. This issue is one of six selected each year by our series consulting editor, Dr. Sujana S. Chandrasekhar. Articles in this issue include: Biologics in otolaryngology overview, Current evidence for biologic therapy in chronic rhinosinusitis with nasal polyposis, Choosing the right patient for biologic therapy in CRSwNP, Knowledge gaps and research needs for biologic therapy in rhinology practice, Mechanisms and practical use of biologic therapies for allergy and asthma indications, Immunotherapeutic strategies in head and neck cancer, Cetuximab in head and neck cancer, Anti-PD-1 immune checkpoint blockade for head and neck cancer, Advances in adoptive cell therapy for head and neck cancer, Biologics for the treatment of recurrent respiratory papillomatosis, Past and future biologics for otologic disorders, Biological treatments for Neurofibromatosis Type II and other skullbase disorders, and Biologics in treatment of autoimmune ear disorders.
- No. of pages:
- © Elsevier 2021
- 28th August 2021
- Hardcover ISBN:
Associate Professor Department of Otolaryngology–Head and Neck Emory University Atlanta, GA, USA
Directory of Otology and Neurotology The George Washington Medical Faculty Associates Washington, DC, USA
Department of Otolaryngology-Head and Neck Surgery, Emory University
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.